Quarterly Consolidated Statement Of Cash Flows

JCR Pharmaceuticals Co.,Ltd. - Filing #7251173

Concept As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-3,201,000,000 JPY
7,280,000,000 JPY
Interest and dividends received
147,000,000 JPY
138,000,000 JPY
Interest paid
-147,000,000 JPY
-87,000,000 JPY
Net cash provided by (used in) operating activities
-5,486,000,000 JPY
9,312,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-9,888,000,000 JPY
-1,526,000,000 JPY
Other, net
-131,000,000 JPY
-564,000,000 JPY
Net cash provided by (used in) investing activities
-9,874,000,000 JPY
-2,690,000,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
750,000,000 JPY
9,600,000,000 JPY
Repayments of long-term borrowings
-750,000,000 JPY
-1,700,000,000 JPY
Redemption of bonds
JPY
-500,000,000 JPY
Purchase of treasury shares
-2,530,000,000 JPY
0 JPY
Dividends paid
-2,505,000,000 JPY
-2,500,000,000 JPY
Other, net
-54,000,000 JPY
-46,000,000 JPY
Net cash provided by (used in) financing activities
9,736,000,000 JPY
-2,031,000,000 JPY
Effect of exchange rate change on cash and cash equivalents
64,000,000 JPY
886,000,000 JPY
Net increase (decrease) in cash and cash equivalents
-5,559,000,000 JPY
5,477,000,000 JPY
Cash and cash equivalents
13,196,000,000 JPY
18,756,000,000 JPY
13,278,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.